Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13562967 | 1.00 | LMNA (0.35) | LMNACYP1A2THRBBLMCREBBP | |
| Trimelamol SCHEMBL1419460 | 0.89 | LMNA (0.42) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL12656824 | 0.89 | MAPT (0.39) | SLC29A1TSHR | |
| SCHEMBL10156085 | 0.87 | CYP1A2 (0.44) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL1309901 | 0.82 | LMNA (0.58) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL1817804 | 0.82 | LMNA (0.58) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL25739494 | 0.81 | LMNA (0.44) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL13562971 | 0.79 | LMNA (0.61) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL1537657 | 0.79 | LMNA (0.61) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL13562968 | 0.79 | LMNA (0.38) | LMNACYP1A2THRBBLMCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504320-B1 | Melamine based mannich-compounds and a process for obtaining the same | BOREALIS AGROLINZ MELAMINE (AT) | 2015-10-14 | — | — | EP | disclosed |
| US-8802848-B2 | Melamine based mannich-compounds and a process for obtaining the same | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2014-08-12 | — | — | US | disclosed |
| US-20120277429-A1 | Melamine Based Mannich-Compounds and a Process for Obtaining the Same | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2012-11-01 | — | — | US | disclosed |
| US-20120277429-A1 | Melamine Based Mannich-Compounds and a Process for Obtaining the Same | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2012-11-01 | — | — | US | disclosed |
| EP-2332926-A1 | Melamine based Mannich-compounds and a process for obtaining the same | Borealis Agrolinz Melamine GmbH (AT) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011061220-A1 | MELAMINE BASED MANNICH-COMPOUNDS AND A PROCESS FOR OBTAINING THE SAME | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277429-A1 | Melamine Based Mannich-Compounds and a Process for Obtaining the Same | MAN2A1, MANBA, MAN2B2 | LMNA 297/4885CYP1A2 332/4885THRB 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.